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ABSTRACT 
Purpose: Evidence on the association between depression, antidepressant use and venous 
thromboembolism (VTE) risk is conflicting. We conducted a systematic review and meta-analysis of 
published observational studies evaluating the associations of depression and antidepressant use with 
VTE risk.  
Design: Eligible studies were identified in a literature search of MEDLINE, Embase, Web of Science 
and reference list of relevant studies up to April 2018. Pooled relative risks (RRs) with 95% 
confidence intervals (CIs) were calculated aggregated using random effects models.  
Results: Eight observational studies with data on 960 113 non-overlapping participants and 9027 
VTE cases were included. The pooled RR (95% CI) for VTE comparing antidepressant use with no 
antidepressant use was 1.27 (1.06-1.51). Tricyclic antidepressants, selective serotonin reuptake 
inhibitors and other antidepressants were each associated with an increased VTE risk; 1.16 (1.06-
1.27), 1.12 (1.02-1.23), and 1.59 (1.21-2.09) respectively. In pooled analysis of three studies that 
compared patients with depression versus individuals without depression, the RR for VTE was 1.31 
(1.13-1.53).  
Conclusion: Pooled observational evidence suggests that depression and use of antidepressants are 
each associated with an increased VTE risk. The effect of antidepressant drugs on VTE may be a class 
effect. The mechanistic pathways underlying these associations deserve further evaluation.  
 
Systematic review registration: PROSPERO 2018: CRD42018095595 
 
Keywords depression; antidepressants; observational study; venous thromboembolism; deep vein 
thrombosis; pulmonary embolism 
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KEY MESSAGES 
• Emerging evidence suggests that depression and antidepressant use may be associated 
with venous thromboembolism (VTE) risk, but the evidence is conflicting. 
• This first systematic review and meta-analysis of observational studies shows that 
depression and use of antidepressants are each associated with an increased risk of VTE. 
• There may be a class effect of antidepressant drugs on VTE. 
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Introduction 
Venous thromboembolism (VTE),  which comprises of deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is an important cause of morbidity, mortality and associated with high health costs.(1, 
2) VTE is regarded as a multifactorial disorder which is determined by genetic, biological, and 
environmental factors.(3) Despite advances in the knowledge of risk factors for VTE and its 
treatment, it remains a global public health problem.(4) Against a background risk from established 
factors such as immobilisation, trauma, surgery, hormonal therapy, obesity, and inherited 
thrombophilia,(5) several other factors might be involved in the development of VTE; this is because 
in a substantial number of VTE cases, the causes are unknown;(6) and the occurrence of VTE is not 
decreasing.(7) This suggests that there are still several yet to be identified factors that are involved in 
the aetiology of VTE. A number of studies have shown that psychosocial factors such as stress, 
depression, anxiety, and low socioeconomic status might be associated with VTE development.(8-11) 
It has been postulated that these factors promote hypercoagulable states through autonomic and 
neuroendocrine pathways.(12) Emerging evidence suggests that  depression and antidepressant use 
may be associated with the development of VTE. A number of population-based observational studies 
have reported on the associations of depression and antidepressant use with subsequent risk of VTE, 
but the results have been conflicting. Whereas some studies have shown evidence of associations,(11, 
13-16) others have found no significant relationships.(17-19) The evidence is uncertain and there is a 
need to summarize all published data on the topic. In this context, we performed a systematic review 
and meta-analysis of all available published observational evidence to clarify and quantify the extent 
of potential associations of depression and antidepressant use with the risk of incident VTE. 
 
Methods 
Data sources and searches 
This review is registered in the PROSPERO prospective register of systematic reviews 
(CRD42018095595) and was conducted using a predefined protocol and in accordance with PRISMA 
and MOOSE guidelines (20, 21). We searched MEDLINE, Embase and Web of Science up to April 
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2018 for population-based observational studies that have evaluated the associations of depression 
and/or antidepressant use with risk of VTE outcomes. The computer-based searches combined terms 
and combined key words related to the exposure (e.g., “depression”, “antidepressant”) and outcome 
(e.g., “venous thromboembolism”, “deep vein thrombosis”, “pulmonary embolism”) in humans 
without language restriction or publication date. Further details on the search strategy are presented in 
Supplementary Table S1. Studies which were reported only as abstracts and not published in their 
full text formats or which were unobtainable as full text copies were excluded. We scanned the 
reference lists of selected studies and review articles for additional studies. 
 
Study selection and eligibility criteria  
Observational longitudinal (prospective cohort, retrospective cohort, nested case-control, or case-
control) studies were eligible for inclusion if they assessed the association of depression and/or 
antidepressant use with first VTE, DVT, or PE events in adults. Studies that reported on recurrent 
VTE were excluded. The initial screening of titles and abstracts was performed by two independent 
authors (S.K.K. and S.S.), after which potentially relevant articles were acquired for full text 
evaluation. The two independent authors assessed each article using the inclusion criteria and any 
disagreements regarding eligibility of an article was discussed and agreement reached by adjudication 
of a third author (K.K.). 
 
Data extraction and quality assessment 
Using a standardized form, we extracted data on study characteristics such as publication year, study 
design, geographical location, baseline age, proportion of males, duration of follow-up, sample size 
and number of VTE events, and risk estimates. Venous thromboembolism outcomes were extracted as 
reported by the eligible studies. The primary outcome of this analysis was composite VTE (DVT 
and/or PE). We also extracted data on the specific endpoints of DVT and PE. Risk estimates for the 
greatest degree of adjustment were extracted. In the case of multiple publications involving the same 
study, the most up-to-date or comprehensive information was abstracted. We assessed study quality 
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using the nine-star Newcastle–Ottawa Scale (NOS)(22) which uses three pre-defined domains 
namely: selection of participants (population representativeness), comparability (adjustment for 
confounders), and ascertainment of outcomes of interest. The NOS assigns a maximum of four points 
for selection, two points for comparability, and three points for outcome. Nine points on the NOS 
reflects the highest study quality. 
 
Statistical analysis 
The summary measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). 
Hazard ratios (HRs) and odds ratios (ORs) were assumed to approximate the same measure of RR 
following Cornfield’s rare disease outcome assumption(23) and also given the fact that the hazard can 
be treated as the instantaneous risk of an event. The inverse variance weighted method was used to 
combine summary measures using random-effects models to account for the effect of between-study  
heterogeneity.(24) We quantified statistical heterogeneity between studies was using the I2 
statistic.(25)  We also estimated 95% prediction intervals which are used to determine the degree of 
heterogeneity, as they provide a region in which about 95% of the true effects of a new study are 
expected to be found.(26, 27) We conducted subgroup analyses by study level characteristics with 
sufficient data using random-effects meta-regression.(28) All statistical tests were two-sided and used 
a significance level of P<0.05 and STATA release 14 (StataCorp LP, College Station, TX, USA) 
software was used for all statistical analyses. 
 
Results 
Study identification and selection 
Our initial search identified 283 potentially relevant citations (Figure 1). After screening the titles and 
abstracts, 11 articles remained for further evaluation. We reviewed these articles and excluded 3 
articles because: (i) outcome was not relevant (n = 1); (ii) study design was not appropriate (n = 1); 
(iii) study duplicated a previous publication using the same cohort (n = 1). In total, there were 8 
eligible articles, which included one article that was identified from manual scanning of the reference 
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lists. The included articles are based on 8 unique observational studies comprising 960 113 
participants and 9027 VTE cases.(11, 13-19) There were 1050 DVT and 79 PE cases. 
 
Study characteristics and quality 
Table 1 provides details of the eligible studies. The mean age of participants at baseline ranged from 
approximately 48 to 68 years, for studies reporting these data. Four studies were based in Europe 
(UK, Norway, and France), two in Asia (Taiwan), one in North America (Canada), and one in the 
Pacific (New Zealand). Five studies explored antidepressant use as an exposure, two studies explored 
depression, and one study explored both antidepressant use and depression. Average duration of 
follow-up to the development of VTE ranged from 0.9 to 13.5 years. The degree of covariate 
adjustment varied, but majority of studies adjusted for VTE established risk factors such as age, body 
mass index, smoking status, and comorbidities. Overall, we judged all of the included studies to be of 
adequate quality (quality score: 6-8).  
 
Depression, antidepressants, and VTE risk 
In pooled analysis of six studies (828 327 participants and 8273 VTE cases), the RR for VTE 
comparing users of antidepressants with non-users was 1.27 (95% CI: 1.06 to 1.51) (Figure 2). The 
95% prediction interval for the pooled RR was 0.73 to 2.18%, suggesting that the true RR for any 
single new study will usually fall within this range. There was evidence of heterogeneity between the 
contributing studies (I2=79%, 53 to 90%; p<0.001). On exclusion of two studies that employed a case-
control design and assigned a quality score of 6 each, the RR for VTE comparing users of 
antidepressants with non-users was 1.28 (95% CI: 1.05 to 1.55). In analysis by type of risk estimate 
reported (HRs vs ORs), the pooled risk estimate of VTE comparing users of antidepressants with non-
users for studies reporting HRs was 1.17 (95% CI: 1.09 to 1.27) and that for studies reporting ORs 
was 1.31 (95% CI: 1.14 to 1.49) (p-value for meta-regression=0.593). Comparing users of 
antidepressants with non-users, the RRs for DVT (one study) and PE (one study) were 1.02 (95% CI: 
0.91 to 1.13) and 4.90 (95% CI: 1.10 to 22.50) respectively. In pooled analysis of two studies (740945 
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participants and 4905 VTE cases), comparing women who used antidepressants versus women who 
did not use them, the RR for VTE was 1.44 (95% CI: 1.29 to 1.61).(14, 15) One study reported a RR 
of 1.38 (95% CI: 0.96 to 1.97) for VTE comparing men who used antidepressants with men who did 
not use antidepressants.(14) In analysis by antidepressant class; tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs), and other antidepressants (comprising of monoamine 
oxidase inhibitors, triazolopyridine, serotonin norepinephrine reuptake inhibitors, or norepinephrine 
dopamine reuptake inhibitors) were each associated with an increased risk of VTE (Figure 3), with no 
significant difference between them (p-value for meta-regression=0.328). 
 
Comparing depression with no depression (3 studies; 865 878 participants; and 4676 VTE cases), the 
pooled RR for VTE was 1.31 (95% CI: 1.13 to 1.53) with a 95% prediction interval of 0.49 to 3.51%. 
(Figure 2). There was no significant evidence of heterogeneity between the contributing studies 
(I2=0%, 0 to 90%; p=0.44). One study reported estimates for the specific outcomes of DVT and PE 
and no significant associations were demonstrated between depression and these endpoints.(13) In 
pooled analysis of two studies (777,578 participants and 4,125 VTE cases),(13, 15) the RR for VTE in 
women comparing depression with no depression was 1.21 (95% CI: 1.02 to 1.45). One study 
reported a RR of 1.65 (95% CI: 1.12 to 2.44) for VTE comparing men with depression versus men no 
depression.(13) 
 
Discussion 
Though a limited number of studies have generally suggested that depression and use of 
antidepressant drugs may each be associated with an excess risk of VTE, the findings have mostly 
been mixed and inconclusive. Indeed, some studies have reported significant associations, whereas 
others have reported null associations. In the largest study conducted to date which comprised over 
700 000 women followed for an average of approximately 7 years, it was reported that women who 
used antidepressants had an increased risk of VTE.(15) However, women who reported treatment for 
depression but not on antidepressants had no significantly increased risk of VTE. By aggregating data 
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from all available epidemiological observational studies, we have shown that antidepressant use (vs 
non-users) as well as depression (vs no depression) are each associated with an increased risk of VTE. 
The associations were more consistent in women. Furthermore, all three classes of antidepressants 
(TCAs, SSRIs, and others) were associated with an increased risk of VTE, with no statistically 
significant difference in their associations. These findings indeed add to accumulating evidence that a 
relationship exists between depression, antidepressant use, and VTE.  
An inflammatory hypothesis has been postulated in the pathogenesis of VTE.(29, 30) Whether the 
associations we have demonstrated is driven by the antidepressant drugs or depression itself or both is 
not very clear. It is difficult to determine this based on evidence from the studies included in this 
review. Based on results from the Million Women Study,(15) which showed that women who 
reported treatment for depression but not on antidepressants did not experience a significant increased 
VTE risk, it has been suggested that the driving force behind VTE development could be due to 
antidepressants rather than the condition itself.(31) Parkin and colleagues hypothesized the observed 
association between antidepressant use and risk of PE could be due to the chemical similarities 
between TCAs (commonly used in treating depression) and phenothiazines.(16) Phenothiazines, 
which are antipsychotics, have been postulated to increase the risk of VTE via increased aggregation 
of platelets,(32) the presence of anticardiolipin antibodies,(33) and exacerbation of venous stasis as a 
result of the sedative effect.(33) Given that the classes of antidepressant are pharmacologically 
distinct and the evidence suggests that VTE risk is similar across the various classes of 
antidepressants, it has also been argued that increased VTE risk may be related to depression itself 
and not due to the antidepressant drugs.(31) A number of pathways have been proposed to explain the 
role of depression in the development of VTE. Depression could impair immobility,(34) which is an 
established risk factor for VTE. Patients with depression are known to have high rates of 
hyperhomocysteinemia,(35) which has been suggested to be associated with an increased risk of 
VTE.(36) Patients with depression may have an elevated VTE risk due to greater platelet activation 
and increased procoagulant activity.(37) Furthermore, it is also possible that the observed associations 
are due to confounding factors such as poor underlying health status, lifestyle, or diet and problems 
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with mobilization, which are common characteristics in some of these patients. The evidence on the 
mechanistic pathways linking depression, antidepressant use, and VTE risk are still speculative. 
Whether the associations are causal or may be just an epiphenomenon, these findings are very 
relevant and underscore the deleterious effects of both depression and antidepressant use on VTE risk. 
Though antidepressant drug groups are pharmacologically distinct in addition to their varying effects, 
our findings suggest there may be a class effect of antidepressant drugs on VTE. Depressive disorders 
are one of leading cause of the global burden of disease and constitute an important cause of years 
lived with disability.(38) Antidepressant drugs have multiple indications, which include anxiety, pain, 
and neuralgia and their use is on the increase on a global scale.(39, 40) Before patients are prescribed 
antidepressants, prescribers may need to conduct further evaluation to determine the excess risk of 
VTE in these patients. However, further studies are still warranted to establish the role of depression 
and antidepressant use in VTE development, their potential causative pathways, and if there is a class 
effect of antidepressants on VTE. Furthermore, additional research is needed to ascertain whether it is 
depression or antidepressant use which drives an increase in VTE risk. These would need to involve 
studies that are able to assess both exposures and provide a way of isolating the effects of one 
exposure from the other. For example, assessing the effect on individuals who are not depressed but 
use antidepressants for a condition such as neurologic or gastrointestinal disease. 
To our knowledge, we have conducted the first systematic review and meta-analysis to summarise 
the evidence on the associations of depression and antidepressant use with the risk of VTE. Though 
the evidence was limited, we were able to harmonize data to perform a quantitative analysis, which 
enhanced power and provided more robust associations compared to the associations reported by 
individual studies. For studies of antidepressant use, we were able to conduct sensitivity analyses by 
type of study design and risk estimates reported and the results were observed to persist. However, the 
few number of studies prevented further evaluation of the associations in clinically relevant subgroups 
such as age, sex, diagnosis of depression (clinical diagnosis vs. diagnosis based on self-reported 
questionnaires), type of VTE (provoked vs unprovoked), severity of depression, and duration of 
depression. There was limited data on the specific outcomes of DVT and PE and therefore their 
 11 
 
associations could not be evaluated in much detail. In addition, pooled analysis was based on variably 
adjusted data reported by the eligible studies, therefore prone to confounding by unmeasured factors. 
However, majority of studies adjusted for relevant confounding factors. Furthermore, the limited 
number of studies (< 10) precluded assessment of publication bias. Finally, estimated prediction 
intervals of the pooled RRs of the associations contained values below 1 and so, although on average 
there seemed to be evidence of associations of depression and antidepressant use with VTE risk, this 
may not always be so in other studies. Further research is needed to replicate these associations and 
identify causes of the heterogeneity between studies. 
 
 
Conclusions 
Pooled observational evidence suggests that depression and use of antidepressants are each associated 
with an increased risk of VTE. The effect of antidepressant drugs on VTE may be a class effect. The 
mechanistic pathways underlying these associations deserve further evaluation.  
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Figure legends 
 
Figure 1. PRISMA flow diagram 
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Figure 2. Associations of depression and antidepressant use with risk of venous thromboembolism 
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Figure 3. Associations of antidepressant groups with risk of venous thromboembolism 
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Table 1. Characteristics of studies included in review 
Lead Author, 
Publication Date 
(Reference) 
Name of study or 
source of 
participants 
Location Study design Year of 
baseline 
survey 
Baseline age 
range (years) 
% 
male 
Follow up 
(years) 
Exposure Outcomes 
reported 
Type of 
risk 
estimate 
No. of 
VTE 
events 
Total 
participants 
Covariates adjusted for Study 
quality 
Enga, 2012 (10) Tromso Norway Prospective cohort 1994-1995 25-96 NR 12.4 Depression VTE  440 25 964 Age, sex, BMI, oestrogens, lifestyle and co-
morbidities 
8 
Lee, 2015 (12) LHID 2000 Taiwan Retrospective cohort 2000 48.0* 38.4 11.0 Depression VTE, 
DVT, and 
PE 
 314 105 822 Age, sex, comorbidities of atrial fibrillation, 
hypertension, diabetes, CVA, heart failure, 
cancer 
8 
Wu, 2013 (13) LHID 2005 Taiwan Nested case-control 2001 63.3‡ 47.7 8.0 Antidepressant 
use 
VTE OR 1,880 13 102 Disease risk score based on comorbid 
medical and psychiatric illnesses (controls 
were matched on age and sex) 
8 
Parkin, 2017 (14) Million Women 
Study 
UK Prospective cohort 1996-2001 59.9* 0.0 7.3 Depression and 
antidepressant 
use 
VTE HR 3,922 734 092 Age, BMI, smoking, alcohol consumption, 
frequency of strenuous physical activity, 
hormone therapy, diabetes mellitus, high 
blood pressure, and socioeconomic status, 
and stratified by recruitment region 
8 
Parkin, 2003 (15) GP database New Zealand Case-control 1990-1998 15-59 NR 12.2-13.5 Antidepressant 
use 
PE OR 13† 263† Weight, combined oral contraceptive use and 
hormone replacement (controls matched on 
sex and year of birth) 
6 
Jick, 2008 (16) UK GPRD UK Nested case-control 1990-2005 ≤ 70 34.8 NR Antidepressant 
use 
VTE OR 782 3867 Smoking, BMI (controls matched on age, 
sex, practice attended by case patient, index 
data, and duration of previous computerized 
record) 
6 
Ray, 2002 (17) Administrative 
database 
Canada Retrospective cohort 1994-2000 ≥ 65 75.0 0.9 Antidepressant 
use 
VTE and 
DVT 
HR 999 75 649 Age, sex, currently residing within a long-
term facility, recent prior hospitalization, 
concurrent diagnosis of cancer, and 
concurrent prescription of ASA, warfarin, 
estrogen or lithium 
7 
Lacut, 2007 (18) University Hospital France Case-control 2000-2004 68.0* 43.3 NR Antidepressant 
use 
VTE OR 677 1354 BMI, factor V Leiden, and prothrombin 
G20210A gene variation (controls were 
matched on age and gender) 
6 
*, average age; †, these numbers are based on subjects without major risk factors for VTE; ‡, mean age of VTE cases; ASA, acetylsalicylic acid; BMI, body mass index; CVA, cerebral vascular accident; DVT, deep 
vein thrombosis; GP, general practitioner; HR, hazard ratio; LHID, Longitudinal Health Insurance Database; NR, not reported; OR, odds ratio; PE, pulmonary embolism; UK GPRD, United Kingdom General Practice 
Research Database; VTE, venous thromboembolism 
 
 
